The finding by scientists at Hoffmann-La Roche that cis-imidazolines could disrupt the protein−protein interaction between p53 and MDM2, thereby inducing apoptosis in cancer cells, raised considerable interest in this scaffold over the past decade. Initial routes to these small molecules (i.e., Nutlin-3) provided only the racemic form, with enantiomers being enriched by chromatographic separation using high-pressure liquid chromatography (HPLC) and a chiral stationary phase. Reported here is the first application of an enantioselective aza-Henry approach to nonsymmetric cis-stilbene diamines and cis-imidazolines. Two novel mono(amidine) organocatalysts (MAM) were discovered to provide high levels of enantioselection (>95% ee) across a broad range of substrate combinations. Furthermore, the versatility of the aza-Henry strategy for preparing nonsymmetric cis-imidazolines is illustrated by a comparison of the roles of aryl nitromethane and aryl aldimine in the key step, which revealed unique substrate electronic effects providing direction for aza-Henry substrate−catalyst matching. This method was used to prepare highly substituted cis-4,5-diaryl imidazolines that project unique aromatic rings, and these were evaluated for MDM2-p53 inhibition in a fluorescence polarization assay. The diversification of access to cis-stilbene diamine-derived imidazolines provided by this platform should streamline their further development as chemical tools for disrupting protein−protein interactions.
■ INTRODUCTION
Initially discovered by high-throughput screening at Hoffman-La Roche (HLR) in 2004, the Nutlins are cis-imidazoline small molecules that inhibit the MDM2-p53 protein−protein interaction (PPI). 1 The Nutlins have been widely used to study the consequences of inducing the activity of the tumor suppressor p53 when it is suppressed by MDM2 in cancer cells. 2 To date, HLR has continued to pursue cancer drug development with the series. 3 The most potent member (and enantiomer) in the original Nutlin family, (−)-Nutlin-3 (1, Chart 1), or Nutlin-3a, is able to selectively disrupt the binding of MDM2 and p53 by mimicking the side chains of key hydrophobic p53 amino acid residues in the MDM2 binding motif. 1 This orthosteric binding releases p53 from its heterodimer complex with MDM2, leading to cell cycle arrest and apoptosis. Since the initial discovery of the Nutlins, a host of structurally different MDM2-p53 inhibitors that function as p53 mimetics have been reported. 4 These small molecules have received much attention from academia and industry in the past decade, since the function of wild-type (WT) p53 is inactivated by overexpression 5 or amplification 6 of MDM2, even though the p53 gene is either deleted or mutated in approximately 50% of all human cancers. 7−9 Additionally, since MDM2 is overexpressed in many types of cancer and functions as a key negative regulator of wild-type p53, the Nutlins have shown promise as anticancer therapeutics. Hoffmann-La Roche (HLR) was the first to advance a Nutlin analogue (RG7112) into clinical trials for solid and hematological tumors. 10, 11 An MDM2 homologueMDMX or MDM4is similarly overexpressed in nearly one-fifth of lung cancers, breast cancers, and retinoblastomas 12, 13 and was most recently found to be overexpressed in ∼65% of human melanomas. 14 Recent reports have since validated MDMX as an additional and valuable therapeutic target. 15−17 The chemistry discussed hereafter has enabled the facile synthesis of a number of enantioenriched cis-imidazolines modeled after (−)-Nutlin that were evaluated for MDM2-p53 inhibition using a previously reported fluorescence polarization competition assay for p53 peptide binding to MDM2. 18 We recently reported the first asymmetric synthesis of (−)-Nutlin-3 (1, Scheme 1). 19, 20 This required the development of a diastereo-and enantioselective aza-Henry reaction with an aryl nitromethane (3a), 21 a pronucleophile used on only two prior occasions but with low levels of selectivity in this context. 22 The β-amino nitroalkane product (4aa) was transformed in five linear steps to (−)-Nutlin-3. Alternatives to prepare Nutlin-3 remain limited to (1) the HLR synthesis of (±)-Nutlin-3 12 followed by chromatographic separation of the enantiomers 23, 24 and (2) a promising enantioselective acylation of symmetric cis-stilbene diamines reported recently by Seidel. 25 Further modifications to our preparation have reduced chromatographic purification of intermediates to one, enabling the preparation of (−)-Nutlin 3 on a multigram scale (>17 g/batch). 20 The use of a diaza-Cope reaction by HLR provided access to a large number of symmetrical cis-stilbene diamines. 26 The diaza-Cope reaction is less amenable to the preparation of cis-imidazolines bearing unique aromatic rings at C4 and C5, and yet access to these small molecules may eventually lead to selective and potent inhibitors of protein−protein interactions. Application of the aza-Henry approach to this problem was not without potential complication. While convergence in the imidazoline synthesis would be well-served (top equation in Figure 1 ), the levels of enantioselectivity can be attenuated by electronic effects. These challenges are often overcome by reagent (catalyst) modification while maintaining a high level of catalyst activity. When successful, this typically provides the most general solution.
Separately, the aza-Henry construction of unsymmetrical cisstilbene diamines offered a strategic question to be examined in conjunction with tactical catalyst development. As outlined in Figure 1 , a single enantiomer of imidazoline 6 bearing unique aromatic substituents can be prepared in two ways using this strategy, on the basis of catalyst antipodes and the roles of the nitroalkane and imine (cf. top and bottom equations in Figure 1 ). The studies reported here detail our work to (1) the identification of a new class of mono(amidine) organocatalyst (MAM) that provides high levels of enantioselection in the aza-Henry addition involving diverse combinations of aryl nitromethane donors and imine acceptors, (2) the implementation and evaluation of parallel pathways to cis-imidazolines 6, and (3) the synthesis and biological evaluation of novel cis-imidazoline MDM2 inhibitors rationally designed from (−)-Nutlin-3. As a result, highly enantioenriched cis-imidazolines bearing either identical or differentiated aryl substituents at C4 and C5 are now more generally accessible and can be applied to therapeutically valuable small molecules.
■ RESULTS AND DISCUSSION
We elected to first study the use of an electron-deficient aldimine (2b) paired with a relatively unbiased aryl nitromethane (3a) using a standard set of conditions (24 h at −20°C). The Bocimine of 3-(trifluoromethoxy) benzaldehyde was prepared in good yield using a standard procedure. 27 Two of our most reactive and selective catalysts were evaluated, 19, 20 and as in previous studies, we hypothesized that the combination of a Brønsted basic catalyst with a Brønsted acidic aryl nitromethane would form a salt (e.g., 7·H +− CH(Ar)NO 2 ) that can, in turn, function as a bifunctional Brønsted acid/Brønsted base in the reaction. First-generation Brønsted basic catalysts (S,S)-PBAM (7) and (R,R)-8 (MeO)PBAM (8) afforded the aza-Henry adduct (ent-4ab and 4ab) in −52% and 61% ee, respectively. Although the reactivity and diastereoselectivity were generally comparable to those of past pyrrolidine bis(amidine) (PBAM) catalysts, the enantioselectivity was diminished. In theory, this may be due to As an alternative to an extensive exploration of the impact of quinoline substituents on enantioselection, 19 an effort that afforded little improvement in this case, we reasoned that the insensitivity of aryl nitromethane additions to added strong acid (e.g., TfOH) might offer the opportunity to explore combinations of amidine and amide functionalities projected from the diamine backbone. The conceptual framework for this modification was also rather different by comparison to previous bis(amidine) modifications. Beginning from its free base form, the catalyst would be expected to form a salt with the aryl nitromethane at the amidine (eq 1, Figure 2 ), but the greatest level of dual activation is expected to involve electrophile binding to the polar ionic hydrogen bond concomitant with nitronate counterion binding to the (amide) polar covalent hydrogen bond. Figure 2 illustrates this conceptually, progressing from substrates and catalyst in A to catalyst-bound product in D. The initial activation event is catalyst deprotonation of the nitroalkane, but in this arrangement (B), the nitronate reactivity may be attenuated by a strong ion pair and imine activation by an amide N−H may be relatively weak. Exchange of the hydrogen bond acceptors (Figure 2, C) , however, leads to a more reactive nitronate due to charge separation and increased activation of the imine. An arrangement such as this might maximize the benefit of drawing the counterion away from the electrophile binding site while providing discrete directional control. Elements of this approach overlap with developments in the field of anion binding catalysis, particularly when the catalyst involves two polar covalent hydrogen bond donors. 28 Other catalyst systems use not only a Brønsted basic catalyst but also a Brønsted base additive (e.g., Et 3 N). 29 The Mono(AMidine) (MAM) catalysts in Scheme 2 were prepared in five steps using an approach that mirrored our preparation of unsymmetrical bis(amidine) ligands in prior studies. 30 Under reaction conditions identical with those used for 7 and 8, (S,S)-PivMAM (ent-9) afforded the addition adduct in an improved −87% ee and 5:1 dr (54% yield), while (S,S)-BenzMAM (ent-10) afforded the adduct in −94% ee and 6:1 dr (62% yield).
A similar comparative analysis was made using aldimine 2a in combination with a range of electronically diverse aryl nitromethanes 3x, yielding adducts 4xa ( Table 1 ). The aryl nitromethanes were prepared from their corresponding and commercially available benzaldehyde derivatives, and all were successful feedstock for the aza-Henry reaction using representative conditions (5 mol % catalyst loading, −20°C, toluene; Table 1 ). We first examined MAM catalyst 10 efficacy with 4-chlorophenyl nitromethane and 4-chlorophenyl Boc-imine ( Table 1 , entry 1), to compare the new catalyst directly to 8; the resulting aza-Henry adduct 4aa can lead to (−)-Nutlin-3 (1). BenzMAM (10) provided the adduct in 96% ee and 53:1 dr at −20°C, in comparison to 91% ee and 13:1 dr at −78°C when using 8 (Table 1, (8) provided the aza-Henry adduct in the highest ee in comparison to PivMAM (9) and BenzMAM (10). The most electron rich case, 3,4-dimethoxyaryl nitromethane ( Table 1 , entry 10), converted with lower enantioselectivity and reaction rate, perhaps due to its diminished Brønsted acidity. Dialing back the electronic effects to (mono)methoxyaryl nitromethane 3i (Table 1 , entry 11), however, reestablishes good levels of stereocontrol (95% ee and >20:1 dr). Interestingly, PivMAM (9) enhanced enantioselectivity for meta-substituted arenes ( Table 1, entries 4, 5, 8, and 9) . For example, the adduct of 3-chloroaryl nitroalkane (Table 1, entry 5) was formed in 89% ee with BenzMAM (10), in comparison to 93% ee when PivMAM (9) (Table 1, entry 4) was employed.
The substrate scope for aryl Boc-imines (2x) was investigated next ( Table 2 ). The synthesis of aryl Boc-aldimines from α-amido sulfones 31 is well established, and a wide array of aldimine substrates can be prepared. 32 A range of aryl Boc-imines was prepared for analysis, leading to β-amino nitroalkanes (4ax) in very high enantio-and diastereoselectivity (up to 99% ee and >200:1 dr; Table 2 ). Haloaryl ( Table 2, entries 1 −5, 7, 8, and 10) , electron-deficient imines ( Table 2 , entries 7−10), and electronneutral ( Table 2 , entry 6) and electron-rich imines ( Table 2 , entries 11 and 12) were transformed to β-amino nitroalkanes in uniformly good to excellent dr/ee and isolated yield.
The behaviors outlined in Table 2 suggest that electronic variations to the aldimine affected stereoselection to a lesser degree than that observed with aryl nitromethane donors. This was more carefully investigated by examining each pairing of aldimine (2) and aryl nitromethane (3) substrates to explore and better gauge reactivity trends (Table 3 ). The arenes selected in Table 3 contain a wide range of functionalities with the purpose of maximizing diversity to a reasonable extent. Using a standard set of reaction conditions, aryl Boc-imines 2 and aryl nitromethanes 3 were combined. Aryl Boc-imines 2j,k and their nitroalkane counterparts 3d,h are notable challenges, as they represent highly electron poor and rich substrates, respectively, in the aza-Henry reaction. As was expected, the ee and dr values observed for neutral and moderately electron deficient aryl nitromethanes are uniformly high (Table 3, entries 1−4 , 3a,b,f,c) . The comparison of ent-4fh with 4cg, however, is an exception to this trend. Under identical reaction conditions with BenzMAM (10), 3-chloro nitroalkane (3c) behaves remarkably better than its imine counterpart (2h) on reaction with the 3-methyl arene partner (99% ee, >20:1 dr by 1 H NMR and 85% ee, 8:1 dr, respectively). A few generalizations can be made from the data generated as well. aza-Henry adducts where the electronpoor 2-fluoro-5-bromo arene is employed as the nitroalkane (3d) consistently resulted in low drpresumably due to the increased α-hydrogen acidity in the product (up to 5:1 dr, 4dg). Fortunately, the 2-fluoro-5-bromoaryl imine (2j) delivers adducts with improved diastereoselectivity and enantioselectivity in specific cases (4fj, 85% ee/40:1 dr, in comparison to 4dg, 68% ee/5:1 dr). In the case of the 3,4-dimethoxyaryl substrate, employing this electron-rich arene as the nitroalkane (3h) proved unsatisfactory (up to 78% ee/20:1 dr, 4hg) in almost every case. Gratifyingly, significantly higher ee and dr was Table 1 . Aza-Henry Additions of Aryl Nitromethanes to p-Chlorophenyl Boc-imine a observed when this arene was employed as the imine (up to 93% ee/56:1 dr, 2k). To further illustrate the value of this observation, entries 4hh and 4ck should be compared. In cases where the adducts were generated in suboptimal ee and dr, switching catalyst antipode and arene pairings proved beneficial in almost all cases, using the tactic outlined in Figure 1 . The 36 compounds outlined in Table 3 represent a wide range of possibilities when targeting symmetrical or unsymmetrical cis-stilbene diamines. These experiments further demonstrate synthetic flexibility using a pair of mono(amidine) (MAM) amide catalysts (9 and 10) to access highly diastereo-and enantiomerically enriched aza-Henry adducts. Table 3 gives adducts that contain either an underlying symmetric cis-stilbene diamine backbone (results along the diagonal from top left to bottom right), or a nonsymmetric cis-stilbene diamine backbone. The latter are constitutional isomers paired on either side of the diagonal. This relationship was considered when converting these intermediates to their derived cis-imidazolines (cf. 5a,b → 6, Figure 1 ). If the two constitutional isomers in Figure 1 are transformed into their derived cis-imidazolines using identical procedures and reagents, the final imidazolines would be enantiomeric at their C4 and C5 carbon centers (although overall constitutionally isomeric cis-imidazolines). However, if the constitutional isomers are formed using enantiomeric catalysts, and the order of steps 2 (amide formation) and 4 (urea formation) is reversed, then the same enantiomer of the cis-imidazoline will be formed, as outlined in Figure 1 . Additionally, the benefits of this method allow for direct and predictable functionalization at a given nitrogen due to their protected nature. Previous attempts at monoderivatization from symmetric (meso) or nonsymmetrical stilbene diamines are notorious for generating a mixture of mono-and disubstituted products. 33 This strategy was reduced to practice using the example in Scheme 3.
In the first case, p-chloro aldimine 2a was converted to 4ba using (R,R)-BenzMAM (10) and p-bromoaryl nitromethane 3b. This adduct was then converted to cis-imidazoline 11 using the five steps outlined in Scheme 3. In the second case, the identities of the aldimine and aryl nitromethane were reversed (to 2c and 3a, respectively), and (S,S)-BenzMAM (ent-10) was deployed to promote a similarly highly diastereo-and enantioselective addition. The adduct 4ac was converted to the corresponding cis-imidazoline, but the amine produced by nitro reduction was subjected to ureaas opposed to amideformation. Deprotection, amide formation, and dehydrative cyclization then furnished the identical cis-imidazoline 11. Hence, by using an enantiomeric catalyst and reversing the order of amide and urea formation in the finishing sequence, the same enantiomer of cis-imidazoline was formed by straightforward permutation of aldimine and aryl nitromethane substrates.
Each case illustrated in Scheme 3 works equally well such that less obvious factors might lead one to choose one route over the other. However, we have identified situations where only one of the two options may be optimal, or even available. For example, we targeted the cis-imidazoline 15 (Scheme 4) bearing p-chloroaryl and m-(trifluoromethoxy)aryl substituents. Attempts to prepare the aryl nitromethane 3i bearing a m-trifluoromethoxy substituent were unsuccessful. Although aldoximine 13 was isolated in 53% yield, a range of oxidants uniformly failed to yield the nitroalkane, presumably due to the electron-withdrawing nature of the substituent (Scheme 4). Conversely, α-amido sulfone formation and its conversion to the corresponding aldimine 2b was successful. Since p-chloroaryl nitromethane 3a is readily available, this combination could be transformed into the desired cis-imidazoline 15 (Scheme 4). By employment of (S,S)-BenzMAM (ent-10), the desired β-amino nitroalkane enantiomer ent-4ab was generated in −94% ee and 6:1 dr (Scheme 5). 34 Nitro group reduction with CoCl 2 and NaBH 4 produced the free amine. Subsequent isocyanate Table 3 . Comparative Analysis of Aldimine−Aryl Nitromethane Reactant Pairs in the Catalyzed Aza-Henry Reaction a,b a All reactions employed 1.1 equiv of nitroalkane in toluene (0.1 M) at −20°C with 24−36 h reaction time. b Catalyst prepared from (R,R)cyclohexanediamine or (S,S)-cyclohexanediamine (denoted ent). Diastereomeric ratio (dr) and enantiomeric excess (ee) were determined by chiral HPLC following vacuum filtration or silica column chromatography (see the Supporting Information). All yields presented are isolated yields. formation using carbonyl diimidazole and its reaction with oxopiperazine 16 led to urea 17. Straightforward Boc deprotection with TFA afforded the free amine, which underwent an acylation with acid 18 using EDC coupling conditions to generate benzamide urea 19. Triphenylphosphine oxide and triflic acid generated a phosphonium anhydride in situ (Hendrickson's reagent), 35 promoting regioselective dehydrative cyclization to provide the imidazoline 15 as a single diastereomer in 94% ee.
This ability to generate nonsymmetrical cis-imidazolines from a host of halogenated arenes could provide a platform for further derivatization using common metal-catalyzed transformations. For example, we postulated that the bromoaryl derivative 11 (Scheme 6) might be functionalized selectively, as oxidative addition should be accelerated in comparison to the neighboring chloroarene. Traditional palladium cross couplings under various conditions to generate new sp 2 −sp 2 C−C bonds or sp 2 carbon− heteroatom bonds should be substrate compatible. 36 We decided to employ traditional Suzuki cross-coupling conditions with Pd(0)−tetrakis(triphenylphosphine) and an aryl boronic ester (20) to test this hypothesis (Scheme 6). 37 After the mixtue was stirred for 24 h at 75°C, formation of the desired pyrazole adduct 21 was confirmed by its isolation in 62% yield. The aryl chloride subunit was clearly intact (confirmed by HRMS), and oxidation to imidazole was not observed. This example establishes the feasibility of late-stage, site-selective functionalization from differentiated haloarenes leading to novel heterocyclic derivatives within this family.
Medicinal Chemistry and SAR. The synthetic studies detailed above were driven in part by a parallel program in the detailed exploration of cis-imidazolines as inhibitors of protein−protein interactions. We investigated the binding sites of MDM2 reported from its cocrystal structure complexed with (−)-Nutlin-3 (PDB 4HG7) to improve the MDM2-p53 (WT) binding inhibitory activity. These compounds are uniformly more potent in their binding to MDM2 as the 4S,5R-configured cis-imidazolines; therefore, their preparation in high ee was considered paramount. As a part of the effort not only to explore MDM2 affinity but also to access structural novelty, our focus was on three hydrophobic side chains that exist within the p53 binding pocket (Phe19, Trp23, and Leu26) and structural modifications were made to both cis-arenes (Ar 1 and Ar 2 , Table 4 ) employing the optimal synthetic pathway (cf. top and bottom equations in Figure 1 ). We also addressed optimization of para substituents of ring A by replacing the electron-donating group (methoxy) with electron-withdrawing groups, including halogens and a nitrile, to explore electrostatic effects. A total of 12 cis-imidazoline analogues were designed and prepared to probe structure−activity relationships (SAR; Table 4 ).
According to recent literature, 38, 39 affinity for MDM2 can be improved by varying the aromatic substituents on the phenyl ring that occupy the Leu26 pocket and by enhancing a π−π stacking Scheme 4. Comparative Analysis: Unsuccessful and Successful Preparations of 3-Trifluoromethoxy Aryl Nitromethane and N-Boc Imine, Respectively interaction with the His96 residue on MDM2. In an attempt to occupy the Leu26 pocket, several analogues were designed and synthesized by introducing different halogens and other functional groups at either the para or meta position on the Ar 2 ring. From the outset, it was clear that any substituents larger than Cl at the meta position slightly decreased the affinity (15, 23, and 27) . However, the only slightly larger p-Br-substituted compound 11 showed potency equivalent with that of 1. An exception to this trend was the N-methylpyrazole 21, which was surprisingly well tolerated given its size. In order to explore possible secondary interactions with a loop of MDM2 crossing the binding site, substituents (halogen, nitrile) were introduced on the para position of the A ring to replace the methoxy group (R group in Table 4 ); no dramatic improvement was observed, but these analogues still exhibited submicromolar affinities (24, 25, 28, and 30). 
■ CONCLUSION
Generalization of the first highly selective aza-Henry addition reaction between aryl nitromethanes and aryl Boc-imines has been achieved, leading to orthogonally protected, cis-stilbene diamine precursors (up to 99% ee as a single diastereomer). The unprecedented selectivity reported for this transformation lies in the discovery of novel mono(amidine) (MAM) bifunctional catalysts that not only afford aza-Henry adducts in high levels of stereocontrol but can achieve this at noncryogenic temperature (−20°C). The goal to generalize these additions to include an array of aryl nitromethanes and aryl Boc-imine substrates was achieved. In cases where a nitroalkane/imine pair led to an addition product with low stereoselection, a strategy-level solution was postulated and reduced to practice, involving a straightforward exchange of nitroalkane/imine identity. By utilization of this methodology, a number of biologically active cis-imidazoline small molecules reminiscent of the Nutlin family were accessed from enantioenriched aza-Henry adducts in subsequent transformations. The realization that constitutionally isomeric products could be transformed to the same cisimidazoline small molecule (see Scheme 3) further improved access, and this was demonstrated in cases where exchange of electrophile and pronucleophile identity in the aza-Henry step led to a combination with markedly higher stereoselection. Operationally, synthetic points of variation for this strategy when pursuing a target synthesis are (1) the sense of the chiral catalyst employed (R,R vs S,S diamine) and (2) the sequence of amine coupling reactionsboth of which are easily manipulated. More broadly, the ability to access enantioenriched, protected cisstilbene diamines now allows for direct and predictable functionalization at each nitrogenan unsolved problem associated with approaches based on meso-stilbene diamine intermediates. Furthermore, unsymmetrical Nutlin-3 analogues bearing differentiated haloarenes can be selectively functionalized via late-stage cross-coupling reactions, allowing for more direct access to analogues for screening aimed at PPI drug discovery efforts.
Among the designed Nutlin analogues, four new compounds (SJ000773209-5, SJ000773211-3, SJ000801055-1, and SJ000801057-1) showed levels of MDM2-p53 inhibition activity similar to that of (−)-Nutlin-3 (1), measured by a fluorescencepolarization assay. These findings provide a robust framework together with a streamlined, enantioselective synthesis in which to develop an in vivo candidate for MDM2-p53 inhibition, as well as pursue cis-imidazoline-class MDMX-p53 inhibitors.
■ EXPERIMENTAL SECTION
All reagents and solvents were commercial grade and were purified prior to use when necessary. Toluene (tol) and dichloromethane (CH 2 Cl 2 ) were dried by passage through a column of activated alumina as described by Grubbs. 40 Aldimines not included were prepared as reported in the literature. 41 Thin-layer chromatography (TLC) was performed using glass-backed silica gel (250 μm) plates, and flash chromatography utilized 230−400 mesh silica gel. UV light and/or the use of potassium iodoplatinate and potassium permanganate solutions were used to visualize products. IRA-900-NO 2 resin was prepared by washing IRA900-Cl resin with aqueous NaNO 2 until the wash no longer tested positive for chloride by an AgNO 3 test.
Nuclear magnetic resonance spectra (NMR) were acquired at 400, 500, or 600 MHz, and chemical shifts were measured relative to residual solvent peaks as an internal standard set to δ 7.26 and 77.0 (CDCl 3 ). IR spectra were recorded as neat films on a NaCl plate (transmission) and are reported in wavenumbers (cm −1 ). Mass spectra were recorded on a high-resolution spectrometer by use of the ionization method noted (APCI or ESI) and used TOF mass analysis. Melting points were measured and are not corrected. Optical rotations were measured using a polarimeter. Absolute and relative configuration of the aza-Henry adducts (4aa−4hk) were assigned by analogy to previously synthesized adducts, for which a crystal structure was obtained. 19 Scheme 7 gives the general scheme to access cis-imidazoline/Nutlin derivatives.
Protein Expression and Purification. GST-MDM2 (1-188) was cloned, expressed, and purified as described previously. 18 Fluorescence Polarization (FP) Assay. The fluorescence polarization (FP) assay was performed with 1 μM GST-MDM2 (1-188) in 10 mM Tris (pH 8.0), 42.5 mM NaCl, and 0.0125% Tween-20 assay buffer. For testing, a dilution series of small molecules (spanning 10 mM to 0.5 μM in DMSO, in 3-fold steps) was added by direct addition to protein using pin transfer (100ss pins, V&P Scientific), giving a test dilution series spanning 65 μM to 3.2 nM with a final concentration of 0.65% DMSO. The increasing concentrations of small molecules dissolved in DMSO were preincubated with protein for 30 min in black 384-well plates and then treated with Texas Red labeled wild-type p53 peptide (15 nM, amino acids 15−29: GSGSSQETFSDLWKLLPEN) and incubated for an additional 45 min. After incubation the FP signal was measured on a multilabel plate reader fitted with a 555 nm excitation filter, 632 nm static and polarized filters, and a Texas Red FP dichroic mirror. Unlabeled WT-p53 peptide was used as a positive control, and DMSO was used as a negative control.
Technical triplicate data were normalized to the positive (100% inhibition) and negative (0% inhibition) controls on the corresponding row of the 384-well plate (percentage inhibition = 100 × ((sample result) − (negative control))/((positive control mean) − (negative control))). Two to seven independent experiments of normalized data were combined into a data set and then fit using a nonlinear regression in GraphPad Prism with the formula log (inhibitor) vs response − variable slope (four parameters). Additionally the residuals of the curve fit were plotted to determine the fit of the theoretical curve. IC50 and 95% confidence intervals (CI) were determined from these graphs.
(E)-tert-Butyl 3-(Trifluoromethoxy)benzylidenecarbamate (2b). In a flame-dried flask equipped with a magnetic stir bar were placed Na 2 SO 4 (384 mg, 2.69 mmol), Cs 2 CO 3 (293 mg, 8.98 μmol), and tert-butyl (tosyl(3-(trifluoromethoxy)phenyl)methyl)carbamate (200 mg, 449 μmol). The solids were suspended in THF (2.2 mL) at room temperature. The mixture was monitored by 1 H NMR and vigorously stirred for 75 min. The solution was filtered through a plug of Celite with excess dichloromethane and concentrated to a white oil which was 90% pure by 1 H NMR (128 mg, about 98%). This material was used without further purification: 1 H NMR (400 MHz, CDCl 3 ) δ 8.82 (s, 1H), 7.80 (d, J = 6.8 Hz, 2H), 7.51 (t, J = 8.0 Hz, 1H), 7.40 (m, 1H), 1.58 (s, 9H) . The extent to which this compound was prone to decomposition precluded acquisition of the remaining analytical data.
(E)-tert-Butyl 4-Iodobenzylidenecarbamate (2e). In a flamedried round-bottom flask equipped with a magnetic stir bar were placed MgSO 4 (888 mg, 7.4 mmol), Cs 2 CO 3 (240 mg, 0.74 mmol), and then tert-butyl ((4-iodophenyl)(tosyl)methyl)carbamate (175 mg, 0.37 mmol). The solids were suspended in THF (2.8 mL), and the mixture was stirred for 4.5 h at room temperature and then filtered through a bed of Celite on an oven-dried frit and washed with dichloromethane. Concentration of the filtrate revealed a white oil (106 mg, 87%) that solidified after sitting in a freezer at −20°C overnight to give a white waxy solid: mp 46°C; R f = 0.40 (20% EtOAc/ hexanes); IR (film) 2978, 2931, 1715, 1629, 1584, 1483 (E)-tert-Butyl 3-Iodobenzylidenecarbamate (2f). In a flamedried flask equipped with a magnetic stir bar were placed Cs 2 CO 3 (488 mg, 1.50 mmol), Na 2 SO 4 (850 mg, 5.99 mmol), and then tert-butyl ((3-iodophenyl)(tosyl)methyl)carbamate (355 mg, 749 μmol) and toluene (7.7 mL). The mixture was vigorously stirred for 2. 167.8, 162.1, 142.1, 138.2, 136.0, 130.5, 129.7, 94.5, 82.7, 27 .9 (3C); HRMS (ESI) exact mass calcd for C 12 (E)-tert-Butyl 5-Bromo-2-fluorobenzylidenecarbamate (2j). In a flame-dried flask equipped with a magnetic stir bar were placed sodium sulfate (7.95 g, 56 mmol), potassium carbonate (6.77 g, 49 mmol), and tert-butyl ((5-bromo-2-fluorophenyl)(tosyl)methyl)carbamate (3.11 g, 7.0 mmol). The solids were suspended in THF (70 mL), and the mixture was refluxed for 7 h, cooled, filtered through an oven-dried frit, and concentrated in vacuo to reveal a white oil (1.881 g, 89%) which solidified to a white waxy solid after being stored at −20°C: mp 39−40°C; R f = 0.47 (30% EtOAc/hexanes); IR (film) 2982, 2930, 1728, 1621, 1584 cm −1 ; 1 H NMR (400 MHz General Procedure for the Preparation of Nitroalkanes 3a−h via Aldoxime. 42 Aldehyde (1.00 mmol), pyridine (1.80 mmol), hydroxylamine hydrochloride (1.20 mmol), and ethanol (333 μL) were combined (in order) in a flask at room temperature. The mixture was stirred for 1−20 h, and ethanol was evaporated under reduced pressure. The mixture was diluted with EtOAc, washed twice with 1 M aqueous HCl, once with saturated aqueous NaHCO 3 , and brine. The organic layer was dried (MgSO 4 ), filtered, and concentrated to a white crystalline solid. Flash column chromatography was used if needed.
The aldoxime (1.00 mmol), MCPBA (2.0−3.0 mmol), and dichloromethane (1.0 mL) were combined in a flask at room temperature. The reaction was monitored by TLC or 1 H NMR, and after 1−3 days the mixture was quenched with saturated aqueous NaHCO 3 and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried (MgSO 4 ), filtered, and concentrated. Column chromatography (SiO 2 , MeOH/dichloromethane) of the residue provided the title compound.
5-Bromo-2-fluoro-4-(nitromethyl)benzene (3d). (E)-5-Bromo-2-fluorobenzaldehyde oxime (1.01 g, 4.63 mmol), MCPBA (1.60 g, 9. 27 mmol), and dichloromethane were combined in a flask at room temperature. After 48 h, the mixture was quenched with saturated aqueous NaHCO 3 and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried (MgSO 4 ), filtered, and concentrated. Column chromatography (SiO 2 , 0−2% methanol in dichloromethane) of the residue provided the compound as a bronze oil (502 mg, 46%): R f = 0.85 (CH 2 Cl 2 ); IR (film) 3074, 2915, 2369, 1761, 1560, 1491 1,2-Dimethoxy-4-(nitromethyl)benzene (3h). 3,4-Dimethoxybenzaldehyde (3.0 g, 18.0 mmol), hydroxylamine hydrochloride (1.50 g, 21.7 mmol), pyridine (2.62 mL, 32.5 mmol) , and ethanol (6.0 mL) were combined in a flask at room temperature. The mixture was stirred for 15 h, and ethanol was evaporated under reduced pressure. The mixture was diluted with EtOAc and washed twice with 1 M aqueous HCl and once with saturated aqueous NaHCO 3 and brine. The organic layer was dried (MgSO 4 ), filtered, and concentrated to a white crystalline solid. This material was carried on without further purification. The resulting aldoxime (3.3 g, 18.2 mmol), MCPBA (6.29 g, 36.4 mmol), and dichloromethane (18 mL) were combined in a flask at room temperature. After 18 h, the mixture was quenched with saturated aqueous NaHCO 3 and the aqueous layer was extracted with dichloromethane. The combined organic layers were dried (MgSO 4 ), filtered, and concentrated. Column chromatography (SiO 2 , dichloromethane) of the residue provided the compound as a yellow solid (1.26 g, 36%) : mp 66−67°C; R f = 0.9 (CH 2 Cl 2 ); IR (film) 3016, 2948, 2838, 1554, 1506, 1376 1-Methoxy-3-(nitromethyl)benzene (3i). In a 200 mL flask were placed silver nitrite (1.68 g, 10.94 mmol) and 1-methoxy-3-benzyl bromide (2.0 g, 9.95 mmol) . The flask was purged with N 2 and covered with aluminum foil. At room temperature, THF (80 mL) was added via syringe. The reaction mixture was stirred at room temperature in the dark for 46 h and then filtered and concentrated. The crude product was purified on a column (SiO 2 , 0−20% ethyl acetate in hexanes) to give the desired product as a pale yellow solid (0.60 g, 36%): R f = 0.9 (CH 2 Cl 2 ); IR (film) 3069, 2916, 2365, 1760, 1558, 1310 General Procedure for Amidine−Amide Catalyst Preparation (9, 10). The synthesis was derived from the previously reported assembly of chiral bis(amidine) catalysts. 43 2-((1R,2R)-2-((4-Chloroquinolin-2-yl)amino)cyclohexyl)isoindoline-1,3-dione (S1). A flame-dried flask equipped with a stir bar was charged with Pd(dba) 2 (208 mg, 362 μmol), rac-BINAP (225 mg, μmol), cesium carbonate (8.84 g, 27.1 mmol), the amine (2.21 g, 9.05 mmol), and 2,4-dichloroquinoline (1.79 g, 9.05 mmol) . An oven-dried condenser was attached, and the apparatus was purged twice with argon. Toluene (45 mL) was added, and the resulting solution was stirred under reflux for 27 h. The reaction mixture was then cooled to room temperature, filtered through a Celite pad with CH 2 Cl 2 and EtOAc, and concentrated. Flash column chromatography of the residue afforded the desired product as a light yellow foam (1.53 126.3, 123.3, 122.4, 122.3, 120.9, 111.0, 56.1, 51.3, 33.4, 28.7, 25.5, 24.8; HRMS (ESI) (1R,2R)-N1-(4-Chloroquinolin-2-yl)cyclohexane-1,2-diamine (S2). In a flask equipped with a stir bar were placed the quinoline (596 mg, 1.47 mmol) and ethanol (3 mL), and the resulting solution was stirred at room temperature for 5 min. Hydrazine monohydrate (264 μL, 5.43 mmol) was added, and the reaction mixture was stirred under reflux for 3 h, whereupon a white solid precipitated out of solution. After the reaction mixture was cooled to room temperature, the solid was washed with ether and filtered. The remaining solid was triturated with ether, the suspension was filtered once more, and the filtrate was concentrated to an orange foam (401 mg, 99%): [α] 7, 148.5, 142.4, 130.2, 126.1, 123.7, 122.3, 121.3, 111.0, 57.4, 55.8, 35.2, 32.5, 24.9, 24.8; HRMS (ESI) N-((1R,2R)-2-((4-Chloroquinolin-2-yl)amino)cyclohexyl)-3,5bis(trifluoromethyl)benzamide (S3). In a flame-dried flask equipped with a stir bar were placed the amine (200 mg, 725 μmol), the carboxylic acid (187 mg, 725 μmol), and dichloromethane (4 mL). The resulting solution was chilled to 0°C, and EDC (181 mg, 943 μmol) and DMAP (9.00 mg, 72.5 μmol) were added. The reaction mixture was stirred and gradually warmed to room temperature. After 20 h, the reaction mixture was diluted with water and extracted with CH 2 N-((1R,2R)-2-((4-Chloroquinolin-2-yl)amino)cyclohexyl)pivalamide (S4). In a flame-dried flask equipped with a stir bar were placed the amine (60.0 mg, 218 μmol) and dichloromethane (3 mL), immediately followed by the addition of N,N-diisopropylethylamine (46.0 μL, 261 μmol), the acid chloride ( 1, 156.7, 148.3, 142.6, 130.5, 126.2, 124.0, 122.6, 121.6, 112.2, 56.1, 53.5, 38.4, 33.1, 32.5, 27.3, 25.1, 24.7; HRMS (ESI) N-((1R,2R)-2-((4-(Pyrrolidin-1-yl)quinolin-2-yl)amino)cyclohexyl)pivalamide (9). A 0.5−2 mL microwave vial was charged with N-((1R,2R)-2-((4-chloroquinolin-2-yl)amino)cyclohexyl)pivalamide (40.0 mg, 111 μmol), pyrrolidine (37.0 μL, 445 μmol), and trifluorotoluene (800 μL). This suspension was heated at 150°C and stirred in the microwave for 90 min. The reaction mixture was concentrated and purified by flash column chromatography (1−10% methanol in dichloromethane w/1% AcOH) to provide a yellow oil. This material was diluted with dichloromethane and washed with 6 M aqueous NaOH. The organic layers were combined and washed three times more with 3 M aqueous NaOH. The combined organic layers were dried (MgSO 4 ) and concentrated to afford a tan amorphous solid (23.5 mg, 54%): mp 251−256°C; [α] 1, 153.9, 149.6, 128.7, 126.6, 124.9, 119.8, 118.8, 92.0, 57.5, 52.3, 52.0, 38.3, 33.5, 32.4, 27.3, 25.8, 25.4, 24.6; HRMS (ESI) 2, 158.3, 154.0, 149.0, 137.6, 131.5 (q, J FC = 33.7 Hz, 1C), 129.3, 127.3, 126.1, 124.9, 124.2, 122.8 (q, J = 273.1 Hz, 1C), 120.3, 118.6, 91.2, 59.6, 53.1, 51.9, 33.3, 31.9, 25.8, 25.5, 24.4 General Procedure for Enantioselective Aza-Henry Additions (4aa−hk). Aryl Boc-imine (4a−k; 100 μmol) and BenzMAM (10; 2.8 mg, 5.0 μmol) or PivMAM (9; 2.0 mg, 5.0 μmol) were dispensed into a flame-dried vial with a stir bar. Toluene (1.0 mL) was added, and the reaction was stirred at room temperature until homogeneous. The reaction mixture was chilled to −78°C before the aryl nitroalkane 3a−i (110 μmol) was added. The reaction mixture was warmed to −20°C and stirred for 18−60 h. The chilled mixture was either diluted with Cl 2 to dissolve precipitate and quickly flushed through a pad of silica gel or diluted with cold hexanes and filtered through a Buchner funnel with filter paper (scale ≥0.2 mmol). Vacuum filtration with cold hexanes resulted in analytically pure material. If the product was added to silica, the pad was flushed with CH 2 Cl 2 , the filtrate was concentrated, and the residue was purified by column chromatography (SiO 2 , ethyl acetate in hexanes), if needed.
tert-Butyl ((1R,2S)-2-(4-Chlorophenyl)-2-nitro-1-(3-(trifluoromethoxy)phenyl)ethyl)carbamate (4ab). Imine 2b (163 mg, 564 μmol) and (S,S)-10 (15.4 mg, 28 μmol) were placed in a flask in toluene (5.6 mL) under argon. The mixture was cooled to −20°C, and nitroalkane 3a (106 mg, 620 μmol) was added. After 48 h the reaction mixture was filtered through a plug of silica gel and concentrated. Column chromatography (SiO 2 , 0−15% ethyl acetate in hexanes) afforded the product as a white crystalline solid (160 mg, 62%). The major diastereomer was determined to be 94% ee and the minor to be 92% ee, with 6:1 dr determined by chiral HPLC (Chiralcel AD: 6% i PrOH/hexanes, 1.0 mL/min: t r (d 2 e 2 minor/minor) = 11.5 min, t r (d 1 e 1 major/major) = 13.4 min, t r 7, 154.3, 139.5, 136.6, 130.5, 130.0, 129.6, 129.3, 129.2 (2C), 125.7, 125.4, 124.7, 121.2, 120.4 (q, 1 2, 134.8, 132.1, 130.3, 129.3, 129.0, 128.6, 128.2, 124.8, 93.2, 30.9, 28.0; HRMS (ESI) tert-Butyl ((1R,2S)-2-(3-Chlorophenyl)-1-(4-chlorophenyl)-2nitroethyl)carbamate (4ca). This compound was prepared according to the general procedure employing catalyst (R,R)-9 (5 mol %) with a 48 h reaction time. The reaction precipitate was added to the filter paper a Buchner funnel and washed with cold hexanes to afford the product as a white crystalline solid (35 mg, 81%) that was found to be 93% ee and >200:1 dr by chiral HPLC (Chiralcel IA: 9% i PrOH/hexanes, 0.6 mL/min: t r (d 1 e 1 major/major) = 12.6 min, t r (d 2 e 1 minor/major) = 15.0 min, t r (d 1 e 2 major/minor) = 17.1 min, t r (d 2 e 2 minor/minor) = 18.6 2, 134.9, 134.8, 133.1, 130.5, 130.3, 130.2, 130.1, 129.3, 129.1, 128.9, 128.6, 128.3, 128.0, 126.8, 93.2, 28.1; HRMS (ESI) tert-Butyl ((1R,2S)-2-(5-Bromo-2-fluorophenyl)-1-(4-chlorophenyl)-2-nitroethyl)carbamate (4da). The reaction was run with catalyst (R,R)-8 (2 mol %) at −78°C for 8 h and the mixture was then warmed to −20°C for an additional 24 h. Following silica plug removal of the catalyst, column chromatography (SiO 2 , 0−10% ethyl acetate in hexanes) afforded the product as a white crystalline solid (422 mg, 65%). The major diastereomer was determined to be 92% ee and the minor to be 90% ee, with 3:1 dr determined by chiral HPLC (Chiralcel IA: 10% i PrOH/hexanes, 0.8 mL/min: t r (d 1 e 1 minor/major) = 17.6 min, t r (d 1 e 2 minor/minor) = 18.6 min, t r (d 2 e 1 major/major) = 20.9 min, t r 6, 135.3, 135.0, 134.9, 130.9, 129.4, 129.2, 128.5, 128.2 (d, 3 J CF = 4 Hz), 127.9 (d, 3 J CF = 4 Hz), 120.8 (d, 2 J CF = 24 Hz), 117.3, 85.4, 28.0; HRMS (APCI) exact mass calcd for C 19 tert-Butyl ((1S,2R)-1-(4-Chlorophenyl)-2-(3-fluorophenyl)-2nitroethyl)carbamate (4ea). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 48 h reaction time. The reaction precipitate was added to the filter paper of a Buchner funnel and washed with cold hexanes to afford the adduct as a white crystalline solid (42 mg, 54%), which was found to be 35:1 dr and 92% ee by chiral HPLC analysis (Chiralpak AD-H, 8% iPrOH/ hexanes, 1 mL/min, t r (d 1 e 1 , major/major) = 21.6 min, t r (d 2 e 2 , minor/ minor) = 23.8 min, t r (d 2 e 2 , minor/minor) = 30.9 min, t r (d 1 e 2 , major/ minor) = 40.2 min): mp 162−164°C; R f = 0.53 (33% EtOAc/hexanes); IR (film) 3379, 2977, 1680, 1553, 1523, 1289, 1252, 1160 8, 161.3, 154.2, 135.6, 134.8, 133.4, 133.3, 131.2, 130.5, 130.4, 129.2, 129.1, 129.0, 128.6, 128.3, 128.2, 125.2, 124.5, 117.5, 117.3, 115.9, 115.6, 93.2, 93.1, 80.8, 28.2, 28.1, 28.0, 27.8 tert-Butyl ((1R,2S)-1-(4-Chlorophenyl)-2-nitro-2-(m-tolyl)ethyl)carbamate (4fa). This compound was prepared according to the general procedure employing catalyst (R,R)-9 (5 mol %) with a 60 h reaction time. Column chromatography (SiO 2 , 0−5% ethyl acetate in hexanes) afforded the adduct as a white crystalline solid (22 mg, 65%), which was found to be 21:1 dr and 93% ee by chiral HPLC analysis (Chiralpak AD-H, 10% i PrOH/hexanes, 1.0 mL/min: t r (d 2 e 1 , minor/ major) =17.9 min, t r (d 1 e 2,, major/minor) = 22.0 min, t r (d 2 e 2 , minor/ minor) = 26.3, t r (d 1 e 1 , major/major) = 32.0 min). The 79% ee and 34:1 dr material was used for optical rotation: [α] 8, 134.5, 131.4, 131.1, 130.8, 129.1, 128.8, 128.6, 125.6, 94.0, 68.1, 38.7, 28.9, 28.2, 28.0, 23.7, 22.9, 21.3 tert-Butyl ((1R,2S)-2-(3-Bromophenyl)-1-(4-chlorophenyl)-2nitroethyl)carbamate (4ga). This compound was prepared according to the general procedure employing catalyst (R,R)-9 (5 mol %) with a 48 h reaction time. The crude product that precipitated out was filtered and washed with cold hexanes to give a off-white crystalline solid (740 mg, 78%) that was found to be 92% ee and 25:1 dr by chiral HPLC (Chiralcel AD-H: 8% EtOH/hexanes, 1.0 mL/min: t r (d 1 e 2 major/ minor) = 11.5 min, t r (d 2 e 1 minor/major) = 14.0 min, t r (d 1 e 1 minor/ minor) = 18.6 min, t r (d 2 e 2 major/major) = 21. 8, 138.2, 135.9, 135.5, 134.4, 133.0, 131.7, 130.3, 130.0, 128.6, 123.5, 94.5, 80.9, 57.1, 28.4 ; HRMS (ESI) exact mass calcd for C 19 off-white solid (56.0 mg, 76%) that was found to be 76% ee and 37:1 dr by chiral HPLC (Chiralcel IA: 12% i PrOH/hexanes, 1.0 mL/min: t r (d 2 e 1 minor/major) = 16.9 min, t r (d 1 e 1 major/major) = 19.2 min, t r (d 1 e 2 major/minor) = 20.1 min, t r 150.7, 149.2, 136.2, 134.6, 129.2, 128.6, 123.5, 122.1, 110.9, 93.9, 80.6, 56 .0 (2C), 28.1; HRMS (ESI) exact mass calcd for C 21 H 25 ClN 2 NaO 6 [M + Na] + 459.1299, found 459.1309.
tert-Butyl ((1R,2S)-1-(4-Chlorophenyl)-2-(3-methoxyphenyl)-2-nitroethyl)carbamate (4ia). The reaction employed catalyst (R,R)-9 (5 mol %) with a 48 h reaction time. The crude precipitated product was filtered and washed with cold hexanes to give a white solid (1.05 g, 87%) that was found to be 95% ee and 23:1 dr by chiral HPLC (Chiralcel AD: 10% EtOH/hexanes, 1.0 mL/min: t r (d 2 e 1 minor/major) = 9.1 min, t r (d 1 e 1 major/major) = 11.3 min, t r (d 2 e 2 minor/minor) = 13.0 min, t r (d 1 e 2 major/minor) = 32.1 min): 1 tert-Butyl ((1S,2R)-1-(4-Bromophenyl)-2-(4-chlorophenyl)-2nitroethyl)carbamate (ent-4ac). This compound was prepared according to the general procedure employing catalyst (S,S)-10 (5 mol %)with a 36 h reaction time. The reaction precipitate was added to the filter paper in a Buchner funnel and washed with cold hexanes to afford the adduct as a white crystalline solid (310 mg, 88%) that was found to be 93% ee with >200:1 dr determined by chiral HPLC (Chiralcel AD-H: 15% i PrOH/hexanes, 1.0 mL/min: t r (d 1 e 1 major/ major) = 10.5 min, t r tert-Butyl ((1R,2S)-2-(4-Chlorophenyl)-1-(4-fluorophenyl)-2nitroethyl)carbamate (4ad). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 48 h reaction time. Column chromatography (SiO 2, 1−10% ethyl acetate in hexanes) afforded the adduct as an off-white crystalline solid (21 mg, 82%) that was found to be 94% ee and 9:1 dr by chiral HPLC (Chiralcel AD-H: 8% i PrOH/hexanes, 1.0 mL/min: t r (d 1 e 2 major/ minor) = 11.7 min, t r (d 2 e 1 major/minor) = 19.6 min, t r (d 1 e 1 major/ major) = 25.7 min, t r (d 2 e 2 minor/minor) = 40. 2 min tert-Butyl ((1S,2R)-2-(4-Chlorophenyl)-1-(4-iodophenyl)-2nitroethyl)carbamate (ent-4ae). This compound was prepared according to the general procedure employing catalyst (S,S)-10 (5 mol %) with a 24 h reaction time. Column chromatography (SiO 2 , 0−5% ethyl acetate in hexanes) afforded the adduct as a white crystalline solid (27 mg, 84%) that was found to be a 99% ee and >100:1 dr by chiral HPLC; (ChiralPak AD-H, 15% i PrOH/hexanes, 1.0 mL/min: t r (d 1 e 1 , major/major) = 11.8 min, t r (d 2 e 1 , minor/major) = 14.1 min, t r (d 1 e 1 , major/major) = 22.8 min, t r (d 2 e 2 , minor/minor = 42.4 min): [α] = 8.4 Hz, 2H), 7.49 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H), 5.75 (d, J = 8.8 Hz, 1H), 5.55 (dd, J = 9.4, 8.8 Hz, 1H), 4.76 (d, J = 9.2 Hz, 1H ), 1.27 (s, 9H); 13 C NMR (100.6 MHz, (CD 3 ) 2 SO) ppm 154. 7, 138.4, 137.9, 135.4, 131.1, 130.9, 130.3, 129.2, 95.3, 92.9, 79.2, 55.9, 28.2; HRMS (ESI) exact mass calcd for C 19 tert-Butyl ((1S,2R)-2-(4-Chlorophenyl)-1-(3-iodophenyl)-2nitroethyl)carbamate (ent-4af). This compound was prepared according to the general procedure employing catalyst (S,S)-9 (5 mol %) with a 72 h reaction time. The reaction precipitate was added to the filter paper of a Buchner funnel and washed with cold hexanes to afford the adduct as a white crystalline solid (360 mg, 80%). The major diastereomer was determined to be 99% ee with >200:1 dr determined by chiral HPLC (Chiralcel AD-H: 15% i PrOH/hexanes, 0.6 mL/min: 1, 139.4, 138.0, 136.6, 136.1, 130.7, 130.1, 129.7, 129.4, 129.1, 126.6, 94.8, 93.1, 28.0; HRMS (ESI) tert-Butyl ((1R,2S)-2-(4-Chlorophenyl)-2-nitro-1-(m-tolyl)ethyl)carbamate (4ag). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 48 h reaction time, and following silica filtration the product was isolated as a white crystalline solid (48 mg, 98% overall) that was found to be 88% ee and 50:1 dr by chiral HPLC (Chiralpak IA, 10% i PrOH/hexanes, 1 mL/min, t r (d 1 e 1 major/major) = 9.6 min, t r (d 2 e 2 minor/minor) = 12.4 min, t r (d 1 e 2 minor/major) = 14.9, t r (d 1 e 2 major/minor) = 32.7 min): [α] 2, 138.9, 137.0, 136.3, 130.2, 130.0, 129.7, 129.0, 128.9, 127.9, 124.0, 94.6, 80.4, 56.5, 28.0, 21.4; HRMS (ESI) tert-Butyl ((1R,2S)-1-(3-Chlorophenyl)-2-(4-chlorophenyl)-2nitroethyl)carbamate (4ah). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 24 h reaction time. Column chromatography (SiO 2 , 0−5% ethyl acetate in hexanes) afforded the adduct as a white crystalline solid (23 mg, 71%) that was found to be 97% ee and 9:1 dr determined by chiral HPLC (Chiralcel IA: 5% i PrOH/hexanes, 1.0 mL/min: t r (d 2 e 2 minor/minor) = 18.4 min, t r (d 2 e 1 minor/major) = 21.3 min, t r (d 1 e 1 major/major) = 31.3 min, t r 71 (br d, 1H ), 1.28 (s, 9H); 13 C NMR (100 MHz, CDCl 3 ) ppm 154. 2, 139.2, 136.6, 135.0, 130.4, 130.1, 129.7, 129.1, 127.4, 125.5, 93.1, 28.0; HRMS (ESI) tert-Butyl ((1R,2S)-2-(4-Chlorophenyl)-1-(3-fluorophenyl)-2nitroethyl)carbamate (4ai). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with an 18 h reaction time, and following silica gel filtration, the product was isolated as a white crystalline solid (37 mg, 98%), which was found to be 60:1 dr and 88% ee by chiral HPLC analysis (Chiralpak AD-H, 5% iPrOH/hexanes, 1.0 mL/min: t r (d 2 e 1 , minor/major) =28.7 min, t r (d 1 e 2 , major/minor) = 34.8 min, t r (d 1 e 1 , major/major) = 48.5, t r (d 2 e 2 , minor/ minor) = 70 min): [α] 1.30 (s, 9 H) ; 13 C NMR (100 MHz, CDCl 3 ) ppm 164. 1, 161.6, 136.6, 130.74, 130.66, 130.0, 129.6, 129.1, 122.8, 116.0, 115.8, 114.4, 114.2, 93.1, 27.9; HRMS (ESI) tert-Butyl ((1R,2S)-1-(5-Bromo-2-fluorophenyl)-2-(4-chlorophenyl)-2-nitroethyl)carbamate (4aj). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 48 h reaction time. Column chromatography (SiO 2, 0−5% ethyl acetate in hexanes) afforded an off-white crystalline solid (29.0 mg, 53%) that was found to be 84% ee and 25:1 dr by chiral HPLC (Chiralcel AD: 6% i PrOH/hexanes, 1.0 mL/min: t r (d 1 e 2 minor/ major) = 12.9 min, t r (d 2 e 1 minor/major) = 14.6 min, t r (d 2 e 2 minor/ minor) = 29.6 min, t r (d 1 e 1 major/major) = 32.8 min) : [α] 1, 136.6, 133.7 (d, 3 J CF = 8.0 Hz), 132. 5, 130.1, 129.5, 129.3, 129.1, 126.0 (d, 3 J CF = 13 Hz), 117.9 (d, 2 J CF = 23 Hz), 117.3, 92.1, 28.1, 27.9; HRMS (ESI) tert-Butyl ((1R,2S)-1,2-bis(4-Bromophenyl)-2-nitroethyl)carbamate (4bc). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 48 h reaction time. Column chromatography (SiO 2, 0−10% ethyl acetate in hexanes) afforded the adduct as a white crystalline solid (19 mg, 75%) that was found to be 84% ee and 9:1 dr by chiral HPLC (Chiralcel IA: 6% i PrOH/hexanes, 1.0 mL/min: t r (d 1 e 1 major/major) = 15.9 min, t r (d 1 e 2 major/minor) = 17.4 min, t r 2, 136.1, 132.3, 132.1, 130.3, 128.9, 128.6, 124.8, 123.0, 93.2, 28.2, 28.0 ; HRMS (ESI) exact mass calcd for C 19 H 20 Br 2 N 2 NaO 4 [M + Na] + 520.9687, found 520.9703.
tert-Butyl ((1R,2S)-1-(4-Bromophenyl)-2-(3-chlorophenyl)-2nitroethyl)carbamate (4cc). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 48 h reaction time. Column chromatography (SiO 2, 0−10% ethyl acetate in hexanes) afforded the adduct as an off-white crystalline solid (23 mg, 80%) that was found to be 95% ee and 5:1 dr by chiral HPLC (Chiralcel IA: 10% i PrOH/hexanes, 0.6 mL/min: t r (d 1 e 1 major/major) = 21.0 min, t r (d 1 e 2 major/minor) = 25.1 min, t r (d 2 e 1 minor/major) = 29.6 min, t r 2, 136.1, 134.8, 133.1, 132.2, 130.5, 130.2, 128.9, 128.6, 126.8, 123.0, 93.1, 28 tert-Butyl ((1R,2S)-2-(5-Bromo-2-fluorophenyl)-1-(4-bromophenyl)-2-nitroethyl)carbamate (4dc). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 36 h reaction time. Column chromatography (SiO 2 , 0−30% ethyl acetate in hexanes) afforded the adduct as an off-white crystalline solid (15.0 mg, 80%) that was found to be 93% ee and 3:1 dr by chiral HPLC (Chiralcel AD-H: 3% EtOH/hexanes, 0.8 mL/min: t r (d 2 e 2 minor/minor) = 22.8 min, t r (d 2 e 1 minor/major) = 25.6 min, t r (d 1 e 1 major/major) = 31.0 min, t r (d 1 e 2 major/minor) = 43.5 min): mp 170−171°C; R f = 0.6 (20% EtOAc/hexanes); IR (film) 3335, 2975, 2926, 1708, 1563, 1486 = 249 Hz), 154.6, 147.9, 135.3, 134.8 (d, 3 J CF = 7.5 Hz), 132.2 (2C), 131. 0, 128.4 (2C), 122.7, 120.9 (d, 3 J CF = 13.5 Hz), 117.7, 117.6, 85.5 (d, 3 J CF = 3 Hz), 28.1; HRMS (ESI) exact mass calcd for C 19 tert-Butyl ((1R,2S)-1-(4-Bromophenyl)-2-nitro-2-(m-tolyl)ethyl)carbamate (4fc). This compound was prepared according to the general procedure employing catalyst (R,R)-9 (5 mol %) with a 48 h reaction time. Column chromatography (SiO 2, 0−10% ethyl acetate in hexanes) afforded the adduct as an off-white crystalline solid (29 mg, 92%) that was found to be 87% ee and 7:1 dr by chiral HPLC (Chiralcel AD-H: 8% i PrOH/hexanes, 1.0 mL/min: t r (d 2 e 1 minor/major) = 25.9 min, t r (d 2 e 2 minor/minor) = 30.8 min, t r (d 1 e 2 major/minor) = 38.3 min, t r (d 1 e 1 major/major) = 43.8 min) : mp 165−166°C; R f = 0.53 (25% EtOAc/hexanes); IR (film) 3379, 2965, 2924, 2848, 1689, 1551, 1517 3, 138.8, 136.8, 131.1, 129.2, 129.0, 128.8, 128.7, 127.5, 125.6, 122.7, 93.9, 29.7, 28.2, 28.0; HRMS (ESI) exact mass calcd for C 20 H 23 BrN 2 NaO 4 [M + Na] + 457.0689, found 457.0696.
tert-Butyl ((1R,2S)-1-(4-Bromophenyl)-2-(3,4-dimethoxyphenyl)-2-nitroethyl)carbamate (4hc). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 72 h reaction time. Column chromatography (SiO 2 , 0−5% ethyl acetate in hexanes) afforded the adduct as a white solid (27 mg, 51%) that was found to be 73% ee and 31:1 dr by chiral HPLC (ChiralPak IA, 7% EtOH/hexanes, 1.0 mL/min: t r (d 1 e 2 major/minor) = 16.1 min, t r (d 1 e 1 major/major) = 18.4 min, t r (d 2 e 2 minor/minor) = 21.0 min, t r 3, 150.7, 149.2, 136.7, 132.1, 129.0 (2C), 128.2, 125.3, 123.5, 122.8, 122.1, 110.9, 93.8, 56.0, 28.1; HRMS (ESI) exact mass calcd for C 21 H 25 BrN 2 NaO 6 [M + Na] + 503.0794; found 503.0777.
tert-Butyl ((1R,2S)-2-(4-Bromophenyl)-2-nitro-1-(m-tolyl)ethyl)carbamate (4bg). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 48 h reaction time. Following silica plug filtration, the adduct was isolated as an off-white solid (35 mg, 88%) that was found to be 85% ee and 68:1 dr by chiral HPLC (Chiralcel IA: 7% i PrOH/hexanes, 1.0 mL/min: t r (d 2 e 1 minor/major) = 15.6 min, t r (d 1 e 2 major/minor) = 17.5 min, t r (d 1 e 1 major/major) = 21.1 min, t r 2, 138.9, 137.0, 132.3, 131.9, 131.6, 130.5, 129.7, 129.0, 127.9, 124.6, 124.0, 93.6, 28.0, 21.4 ; HRMS (ESI) exact mass calcd for C 20 H 23 BrN 2 NaO 4 [M + Na] + , 457.0739, found 457.0720.
tert-Butyl ((1R,2S)-2-(3-Chlorophenyl)-2-nitro-1-(m-tolyl)ethyl)carbamate (4cg). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 48 h reaction time. Following silica plug filtration, the adduct was isolated as an off-white crystalline solid (22 mg, 97%) that was found to be 99% ee and 20:1 dr by chiral HPLC (Chiralcel IA: 8% i PrOH/ hexanes, 1.0 mL/min: t r (d 2 e 2 minor/minor) = 10.5 min, t r (d 1 e 1 major/ major) = 14.1 min, t r (d 1 e 2 major/minor) = 15.5 min, t r tert-Butyl ((1S,2R)-1-(4-Bromophenyl)-2-(4-chlorophenyl)-2nitroethyl)carbamate (4cj). This compound was prepared according to the general procedure employing catalyst (R,R)-9 (5 mol %) with a 48 h reaction time. Column chromatography (SiO 2 , 0−5% ethyl acetate in hexanes) afforded the adduct as a white solid (28 mg, 90%) that was found to be 88% ee and 8:1 dr determined by chiral HPLC (Chiralcel AD-H: 8% i PrOH/hexanes, 1.0 mL/min: t r (d 1 e 2 major/minor) = 10.6 min, t r (d 2 e 1 minor/major) = 13.8 min, t r (d 2 e 2 minor/minor) = 19.1 min, t r = 244 Hz), 133.8, 133.7, 132.8, 130.9 (2C), 130.6, 130.2, 129.1, 128.8 (2C), 126.7, 125.9, 118.0 (d, 2 tert-Butyl ((1R,2S)-1,2-Bis(5-bromo-2-fluorophenyl)-2nitroethyl)carbamate (4dj). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 48 h reaction time. Column chromatography (SiO 2 , 0−5% ethyl acetate in hexanes) afforded the product as a white crystalline solid (22 mg, 56%) that was found to be 78% ee and 2:1 dr by chiral HPLC; (ChiralPak IA, 10% i PrOH/hexanes, 1.0 mL/min: t r (d 1 e 1 major/ major) = 5.9 min, t r (d 2 e 1 minor/major) = 6.5 min, t r (d 2 e 2 minor/ minor) = 7.1 min, t r 7, 133.5, 133.4, 132.1, 131.9, 130.1, 125.6, 120.7, 118.2, 118.0, 117.8, 117.6, 117.4 (2C), 117.2, 84.7, 84.4, 81.2, 81.0, 29.7, 28.3, 28 tert-Butyl ((1R,2S)-1-(5-Bromo-2-fluorophenyl)-2-nitro-2-(mtolyl)ethyl)carbamate (4fj). This compound was prepared according to the general procedure employing catalyst (R,R)-9 (5 mol %) with a 48 h reaction time. Column chromatography (SiO 2 , 5−10% ethyl acetate in hexanes) afforded the adduct as a white crystalline solid (23 mg, 42%) that was found to be 82% ee and 40:1 dr by chiral HPLC (Chiralcel IA: 10% i PrOH/hexanes, 1.0 mL/min: t r (d 2 e 1 minor/major) = 7.4 min, t r (d 1 e 1 major/major) = 14.9 min, t r (d 1 e 2 major/minor) = 6.6 min, t r (d 2 e 2 minor/minor) = 9.2 min): [α] D 20 = −13°(c 0.31, CHCl 3 , 76% ee, 20:1 dr); mp 159−165°C; R f = 0.48 (20% EtOAc in hexanes); IR (film) 3450, 3000, 2950, 2410, 1710, 1590, 1490 , 1260 cm −1 ; 1 H NMR (400 MHz, CDCl 3 ) δ 7.53 (br s, 1H), 7.44 (ddd, J = 8.8, 4.8, 2.8 Hz, 1H), 7.38 (s, 1H), 7.36 (s, 1H), 7.31 (t, J = 7.6 Hz, 1H), 7.25 (s, 1H), 7.00 (dd, J = 10.8, 9.2 Hz, 1H), 5.80 (m, 2H) = 249 Hz), 154.5, 138.7, 133.4, 131.1 (d, 3 J CF = 8 Hz), 130.9, 129.1, 128.8, 125.6, 118.0, 117.5 (d, 2 J CF = 23 Hz), 92.8, 27.9, 21.3; HRMS (ESI) tert-Butyl ((1R,2S)-1-(5-Bromo-2-fluorophenyl)-2-(3,4-dimethoxyphenyl)-2-nitroethyl)carbamate (4hj). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 72 h reaction time. Following silica plug filtration, 1 H NMR showed >20:1 dr. Column chromatography (SiO 2 , 10−40% ethyl acetate in hexanes) afforded the adduct as an off-white solid (31.0 mg, 70%) that was found to be 56% ee and 4:1 dr (racemized on silica) by chiral HPLC (Chiralcel IA: 12% i PrOH/hexanes, 1.0 mL/min: t r (d 1 e 2 major/minor) = 9.5 min, t r (d 2 e 1 minor/major) = 10.3 min, t r (d 2 e 2 minor/minor) = 16.8 min, t r (d 1 e 1 major/major) = 23.4 min) : mp 131− 132°C; R f = 0.66 (50% EtOAc/hexanes); IR (film) 3368, 2974, 2928, 1703, 1556, 1518, 1279 = 8.8, 1.6 Hz, 1H), 6.88 (dd, J = 8.0, 8.0 Hz, 1H), 5.77 (m, 2H), 5.00 (d, J = 8.8 Hz, 1H) , 3.94 (s, 3H), 3.87 (s, 3H), 1.26 (s, 9H) ; 13 C NMR (100 MHz, CDCl 3 ) ppm 154. 2, 150.1 (d, 1 J CF = 253 Hz), 133.5 (d, 3 J CF = 9 Hz), 126.5 (d, 3 J CF = 9 Hz), 123. 2 (d, 2 J CF = 27 Hz), 122.3, 122.1, 117.9 (d, 2 J CF = 23 Hz), 117.3, 112.6, 111.1, 110.8, 110.7, 92.8 (d, 4 J CF = 5 Hz), 80.5, 56.0 (2C) tert-Butyl ((1R,2S)-2-(4-Bromophenyl)-1-(3,4-dimethoxyphenyl)-2-nitroethyl)carbamate (4bk). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 44 h reaction time. The reaction precipitate was added to the filter paper of a Buchner funnel and washed with cold hexanes to afford the product as an off-white crystalline solid (33 mg, 60%) that was found to be 85% ee and 9:1 dr by chiral HPLC (Chiralcel AD-H: 9% EtOH/hexanes, 1.0 mL/min: t r (d 1 e 2 major/minor) = 16.3 min, t r (d 2 e 1 minor/major) = 19.5 min, t r (d 1 e 1 major/major) = 22.4 min, t r (d 2 e 2 major/major) = 53.5 min): mp 153−154°C; R f = 0.19 (25% EtOAc/hexanes); IR (film) 3368, 2973, 2938, 1697, 1551, 1516 cm −1 ; 1 H NMR (400 MHz, CDCl 3 ) δ 7.54 (d, J = 8.8 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 6.86 (m, 3H), 5.76 (d, J = 9.2 Hz, 1H), 5.54 (dd, J = 9.6, 9.2 Hz, 1H), 4.83 (br d, 1H) , 3.87 (s, 3H), 1.28 (s, 9H); 13 C NMR (100 MHz, CDCl 3 ) ppm 154. 3, 149.4, 149.2, 131.9, 130.6, 130.5, 129.5, 124.6, 119.2, 111.3, 110.6, 93.5, 56.0, 55.9, 28.0; HRMS (ESI) tert-Butyl ((1R,2S)-2-(3-Chlorophenyl)-1-(3,4-dimethoxyphenyl)-2-nitroethyl)carbamate (4ck). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 60 h reaction time. Following the silica plug filtration, the resulting white solid was added to the filter paper of a Buchner funnel and washed with cold hexanes to afford the pure compound as an offwhite solid (15. 3 mg, 64%) that was found to be 93% ee and 56:1 dr by chiral HPLC (Chiralcel AD-H: 6% EtOH/hexanes, 1.0 mL/min: t r (d 1 e 2 major/minor) = 19.9 min, t r (d 2 e 1 minor/major) = 23.3 min, t r (d 1 e 1 major/major) = 25.5 min, t r 5.54 (dd, J = 9.6, 9.2 Hz, 1H), 4.80 (d, J = 9.2 Hz, 1H) , 3.88 (s, 3H), 3.87 (s, 3H), 1.28 (s, 9H); 13 C NMR (100 MHz, CDCl 3 ) ppm 154. 2, 149.4, 149.3, 134.6, 133.4, 130.3, 130.0, 129.5, 129.1, 126.9, 119.2, 111.4, 110.6, 93.5, 56.0, 55.9, 28.0; HRMS (ESI) tert-Butyl ((1R,2S)-2-(5-Bromo-2-fluorophenyl)-1-(3,4-dimethoxyphenyl)-2-nitroethyl)carbamate (4dk). This compound was prepared according to the general procedure employing catalyst (R,R)-9 (5 mol %) with a 46 h reaction time. The reaction precipitate was added to the filter paper of a Buchner funnel and washed with cold hexanes to afford the adduct as a white crystalline solid (22 mg, 45%) that was found to be 86% ee and 1.5:1 dr by chiral HPLC (Chiralcel IC: 8% i PrOH/hexanes, 1.0 mL/min: t r (d 2 e 1 minor/major) = 15.1 min, t r (d 1 e 1 major/major) = 16.8 min, t r = 8.8 Hz, 1H), 6.90 (dd, J = 8.4, 1.6 Hz, 1H), 6.85 (m, 2H), 6.12 (d, J = 10.0 Hz, 1H), 5.60 (br d, 1H), 4.82 (d, J = 9.6 Hz, 1H) , 3.90 (s, 3H), 3.88 (s, 3H), 1.29 (s, 9H); 13 C NMR (100 MHz, CDCl 3 ) ppm 159.9 (d, 1 J CF = 240 Hz), 149. 5, 149.4, 134.7 (d, 3 J CF =11 Hz), 132.4 (d, 3 J CF = 9 Hz), 129.2, 126.9, 121.2, 121.1, 119.0, 117.2 (d, 4 J CF = 3 Hz), 111. 5, 85.5 (d, 4 J CF = 2 Hz), 56. 0, 55.9, 28.2, 28.0; HRMS (ESI) 36 (m, 2H), 2H), 6.90 (d, J = 8.0 Hz, 1H), 6.83 (m, 2H), 5.74 (d, J = 9.2 Hz, 1H), 5.58 (dd, J = 9.2, 8.8 Hz, 1H), 4.78 (d, J = 8.8 Hz, 1H) , 3.87 (s, 6H), 2.37 (s, 3H), 1.27 (s, 9H); 13 C NMR (100 MHz, CDCl 3 ) ppm 154.3, 149. 2, 149.1, 138.6, 131.5, 130.9, 130.2, 129.3, 128.7, 125.8, 119.2, 111.3, 110.6, 94.3, 55.9 (2C), 29.7, 28.0, 21.3 ; HRMS (ESI) exact mass calcd for C 22 H 28 N 2 NaO 6 [M + Na] + , 439.1845 [M + Na] + , 439. , found 439.1862 tert-Butyl ((1S,2R)-2-(4-Chlorophenyl)-1-(3,4-dimethoxyphenyl)-2-nitroethyl)carbamate (4ak). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 48 h reaction time. Column chromatography (SiO 2 , 0−5% ethyl acetate in hexanes) afforded the product as a tan crystalline solid (28.3 mg, 54%) that was found to be 92% ee and 25:1 dr by chiral HPLC (ChiralPak AD-H, 10% EtOH/hexanes, 1.0 mL/min: t r (anti, minor) = 13.2 min, t r (syn, major) = 15.8 min, t r (anti, major) = 17.2 min, t r (syn, minor) = 36.8 min) : [α] D 20 = −21°(c 0.36, CHCl 3 ); mp 150−151°C; R f = 0.11 (20% EtOAc in hexanes); IR (film) 3383, 2989, 1676, 1595, 1519, 1463, 1423 , 1367 cm −1 ; 1 H NMR (400 MHz, CDCl 3 ) δ 7.52 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 3H), 5.77 (d, J = 9.2 Hz, 1H), 5.54 (dd, J = 9.4, 9.2 Hz, 1H) , 3.87 (br d, 1H), 3.87 (s, 3H), 3.87 (s, 3H), 1.28 (s, 9H); 13 C NMR (100 MHz, CDCl 3 ) ppm 154. 2, 149.3, 149.2, 136.3, 130.2, 130.0, 129.5, 128.9, 119.1, 111.3, 110.5, 93.4, 80.5, 55.9, 55.8, 29.6, 28.0; HRMS (ESI) (4hk). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 48 h reaction time. Following silica plug filtration, 1 H NMR showed >20:1 dr. Column chromatography (SiO 2 , 10−40% ethyl acetate in hexanes) afforded the adduct as an off-white crystalline solid (23.0 mg, 72%) that was found to be 50% ee and 5:1 dr (epimerized on silica) by chiral HPLC (Chiralcel IA: 12% i PrOH/hexanes, 1.0 mL/min: t r (d 2 e 2 minor/ minor) = 15.4 min, t r (d 1 e 2 major/minor) = 17.8 min, t r (d 1 e 1 major/ major) = 24.8 min, t r (d 2 e 2 minor/minor) = 34.5 min): mp 171°C dec; R f = 0.75 (50% EtOAc/hexanes); IR (film) 3369, 2969, 2930, 2838, 1699, 1553, 1523, 1253 4, 150.5, 149.2, 149.1 (2C), 130.1, 123.9, 122.2, 119.1, 111.3, 122.2, 119.1, 111.1, 111.0, 110.7, 110.6, 94.2, 80.3, 55 .9 (4C), 28.1; HRMS (ESI) exact mass calcd for C 23 H 30 N 2 NaO 8 [M + Na] + 485.1933 [M + Na] + 485. , found 485.1958 tert-Butyl ((1R,2S)-2-(3,4-Dimethoxyphenyl)-2-nitro-1-(mtolyl)ethyl)carbamate (4hg). This compound was prepared according to the general procedure employing catalyst (R,R)-10 (5 mol %) with a 72 h reaction time. The reaction precipitate was added to the filter paper of a Buchner funnel and washed with cold hexanes to afford the product as a light brown crystalline solid (30 mg, 70%) that was found to be 78% ee and 1:1 dr (epimerized from 20: 4, 150.5, 149.0, 138.7, 137.0, 129.5, 128.9, 127.7, 124.0, 122.2, 121.4, 111.1, 111.0, 94.3, 56.0, 28.2, 21 tert-Butyl ((1R,2S)-2-Amino-2-(4-bromophenyl)-1-(4chlorophenyl)ethyl)carbamate (S6). β-Nitro Boc-amine 4ba (470 mg, 1.03 mmol) and CoCl 2 (134 mg, 1.03 mmol) were added to methanol (4.1 mL) in a flask and chilled to 0°C before NaBH 4 (194 mg, 5.15 mmol) was added in three portions over 2 h. The reaction mixture was stirred at 0°C for an additional 15 min before the mixture was quenched with saturated aqueous NH 4 Cl. The reaction mixture was adjusted to pH 10 with concentrated aqueous NH 4 1, 140.8, 133.4, 132.6, 128.7 (2C), 128.3, 121.41, 120.3, 79.8, 59.3, 28.3 (3C) ; HRMS (ESI) exact mass calcd for C 19 tert-Butyl ((1R,2S)-2-(4-Bromophenyl)-1-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxybenzamido)ethyl)carbamate (S7). Amine S6 (383 mg, 900 μmol) and carboxylic acid (189 mg, 900 μmol) were dissolved in CH 2 Cl 2 (4.5 mL), chilled to 0°C, and treated with EDC·HCl (224 mg, 1.17 mmol) and DMAP (10 mg, 90 μmol). The reaction mixture was stirred and gradually warmed to room temperature over 2 h. After 16 h, the mixture was diluted with water and extracted with dichloromethane. The combined organic layers were washed with water, saturated aqueous NaHCO 3 , and once more with water. The organic layer was dried (MgSO 4 ), filtered, and concentrated. The residue was washed with a 3/7 dichloromethane/ hexanes mixture and decanted to afford a white solid (438 mg, 79%) that was >95% pure by 1 H NMR: [α] 6, 163.7, 157.2, 155.1, 137.3, 134.4, 133.4, 131.5, 128.9, 128.7, 128.4, 121.7, 114.2, 105.3, 100.3, 80.0, 71.5, 59.5, 56.7, 55.5, 31.6, 28.3, 22.6, 22.0, 21.6, 14. N-((1S,2R)-2-Amino-1-(4-bromophenyl)-2-(4-chlorophenyl)ethyl)-2-isopropoxy-4-methoxybenzamide (S8). Amide S7 (374 mg, 605 μmol) was dissolved in dichloromethane (6.0 mL), and the solution was treated with TFA (1.8 mL, 24 mmol) and stirred at room temperature for 2 h. The reaction mixture was diluted with dichloromethane, poured into saturated aqueous NaHCO 3 , and extracted with dichloromethane. The combined organic layers were dried (MgSO 4 ), filtered, and concentrated to a white foam (300 mg, 96%): [α] 6, 163.3, 157.2, 140.7, 137.3, 134.1, 133.1, 131.1, 129.5, 128.4, 128.3, 121.4, 114.9, 105.1, 100.3, 71.5, 58.9, 58.6, 55.5, 22.2, 22 N-((1R,2S)-2-(4-Bromophenyl)-1-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxybenzamido)ethyl)-3-oxopiperazine-1-carboxamide (S9). Amine S8 (267 mg, 516 μmol) was added to carbonyl diimidazole (109 mg, 671 μmol) in dichloromethane (1.8 mL) . The mixture was stirred at room temperature for 90 min (or until no starting material remained by TLC), at which point the oxopiperazine (103 mg, 1.03 μmol) was added. The mixture was stirred for 16 h and then diluted with dichloromethane and water. The aqueous layer was extracted with dichloromethane, and the organic layers were combined, dried (MgSO 4 ), filtered, and concentrated to an off-white oil. Column chromatography (SiO 2 , 0−3% methanol in dichloromethane) afforded 167.8, 167.2, 164.0, 157.3, 155.0, 137.0, 136.4, 134.4, 133.3, 131.6, 129.4, 128.7, 128.1, 122.0, 113.4, 105.4, 100.3, 71.5, 61.8, 57.7, 55.6, 47.5, 41.1, 40.0, 22.0, 21.5; HRMS (ESI) tert-Butyl ((1S,2R)-2-Amino-1-(4-bromophenyl)-2-(4chlorophenyl)ethyl)carbamate (S10). β-Nitro Boc-amine 4ac (265 mg, 581 μmol) and CoCl 2 (75.4 mg, 581 μmol) were added to methanol (3 mL) in a flask and chilled to 0°C before NaBH 4 (110 mg, 2.91 mmol) was added in three portions over 45 min. The reaction mixture was stirred at 0°C for an additional 15 min before the mixture was quenched with saturated aqueous NH 4 Cl. The reaction mixture was adjusted to pH 10 with concentrated aqueous NH 4 OH, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried (MgSO 4 ), filtered, and concentrated to a white foam (260 mg, 99%): [α] 0, 140.3, 133.3, 131.5, 131.2, 129.1, 128.4, 128.3, 121.5, 59.1, 28.3 (3C) ; HRMS (ESI) exact mass calcd for C 19 N-((1R,2S)-2-Amino-2-(4-bromophenyl)-1-(4-chlorophenyl)ethyl)-3-oxopiperazine-1-carboxamide (S11). Amine S10 (241 mg, 566 μmol) was added to carbonyl diimidazole (119 mg, 736 μmol) in dichloromethane (2.0 mL). The mixture was stirred at room temperature for 3 h (or until no starting material remained by TLC), at which point the oxopiperazine (113 mg, 1.13 mmol) was added. The mixture was stirred for 16 h and then diluted with dichloromethane and water. The aqueous layer was extracted with dichloromethane, and the organic layers were combined, dried (MgSO 4 ), filtered, and concentrated to an off-white solid. The solid was washed with 1/1 dichloromethane/hexanes (6 mL), and the wash layer was decanted to afford the desired product as a 1/1 mixture with imidazole. This was used without further purification. The urea (230 mg, 417 μmol) was dissolved in dichloromethane (5.0 mL), and the solution was treated with TFA (1.26 mL, 16.0 mmol) and stirred at room temperature for 3 h. The reaction mixture was diluted with dichloromethane, poured into saturated aqueous NaHCO 3 , and extracted with dichloromethane. The combined organic layers were dried (MgSO 4 ), filtered, and concentrated to a brown oil (170 mg, 67% over two steps): [α] 167.3, 155.7, 140.8, 136.7, 133.4, 131.4, 128.8, 128.5 (2C), 128.3, 121.5 (2C), 59.3, 59.1, 47.6, 40.9, 39.7, 29.7; HRMS (ESI) N-((1R,2S)-2-(4-Bromophenyl)-1-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxybenzamido)ethyl)-3-oxopiperazine-1-carboxamide (S12). Amine S11 (116 mg, 257 μmol) and carboxylic acid (54.0 mg, 257 μmol) were dissolved in dichloromethane (1.3 mL), chilled to 0°C, and treated with EDC·HCl (64.0 mg, 334 μmol) and DMAP (3.1 mg, 26 μmol). The reaction mixture was stirred and gradually warmed to room temperature over 2 h. After 5 h, the mixture was diluted with water and extracted with dichloromethane. The combined organic layers were washed with water, saturated aqueous NaHCO 3 , and once more with water. The organic layer was dried (MgSO 4 ), filtered, and concentrated. Column chromatography (SiO 2 , 0−6% methanol in dichloromethane) afforded the amide as a white solid (112 mg, 68%): [α] D 20 = +32°(c 0.65, CHCl 3 ); mp =169°C; R f = 0.60 (10% MeOH/CH 2 Cl 2 ); IR (film) 3367, 2978, 2934, 1638, 1604, 1532, 1492, 1259 167.9, 167.2, 164.0, 157.2, 156.0, 137.1, 136.5, 134.4, 133.3, 131.6, 129.4, 128.7, 128.1, 121.9, 113.5, 105.4, 100.3, 71.5, 61.7, 60.4, 57.7, 55.6, 47.5, 41.1, 40.0, 22.0, 21.5, 21.0, 14.2; HRMS (ESI) cis-Imidazoline 11. Tf 2 O (143 μL, 845 μmol) was added to a stirred solution of Ph 3 PO (470 mg, 1.69 mmol) in dichloromethane (1.0 mL) at 0°C, and this mixture was stirred for 10 min and then treated with the cis-amide urea S11 or S8 (272 mg, 422 μmol) as a solution in dichloromethane (2.0 mL). The mixture was stirred at 0°C for 1 h prior to stirring at room temperature for 4 h. The reaction mixture was quenched with NaHCO 3 , the aqueous layer was extracted with dichloromethane, and the combined organic layers were dried (MgSO 4 ), filtered, and concentrated. Column chromatography (SiO 2 , 0−2% methanol in dichloromethane) of the residue provided the product as a white solid (173 mg, 66%): [α] 9, 163.0, 160.2, 157.0, 154.7, 136.5, 135.0, 133.1, 132.1, 130.9, 129.6, 128.4,128.1, 121.0, 113.4, 104.6, 100.1, 71.8, 70.9, 69.1, 55.5, 49.4, 41.8, 40.3, 22 .0 (2C); HRMS (ESI) exact mass calcd for C 30 H 31 BrClN 4 O 4 [MH] + 625.1217, found 625.1207.
tert-Butyl ((1R,2S)-2-Amino-2-(4-chlorophenyl)-1-(3-(trifluoromethoxy)phenyl)ethyl)carbamate (S17). β-Nitro Bocamine ent-4ab (140 mg, 304 μmol) and CoCl 2 (46.0 mg, 304 μmol) were added to methanol (1.2 mL) in a flask and chilled to 0°C before NaBH 4 (57 mg, 1.5 mmol) was added in three portions over 5 h. The reaction mixture was stirred at 0°C for an additional 15 min before the mixture was quenched with saturated aqueous NH 4 Cl. The reaction mixture was adjusted to pH 10 with concentrated aqueous NH 4 OH, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried (MgSO 4 ), filtered, and concentrated. Column chromatography (SiO 2 , 40−60% ethyl acetate in hexanes) afforded the product as a white foam (60 mg, 46%) 1, 149.0, 140.1, 133.4, 130.6, 129.4, 128.4, 128.2, 125.9, 121.6, 120 .3 (q, 1 J CF = 251 Hz), 120.0, 119.9, 119.1 79.9, 59.1, 28.2; HRMS (ESI) exact mass calcd for C 20 H 23 tert-Butyl ((1R,2S)-2-(4-Chlorophenyl)-2-(3-oxopiperazine-1carboxamido)-1-(3-(trifluoromethoxy)phenyl)ethyl)carbamate (S18). Amine S17 (60 mg, 139 μmol) was added to carbonyl diimidazole (29.4 mg, 181 μmol) in dichloromethane (0.5 mL). The mixture was stirred at room temperature for 90 min (or until no starting material remained by TLC), at which point the oxopiperazine (27.8 mg, 278 μmol) was added. The mixture was stirred for 16 h and then diluted with dichloromethane and water. The aqueous layer was extracted with dichloromethane, and the organic layers were combined, dried (MgSO 4 ), filtered, and concentrated to an off-white oil. The residue was washed with hexanes (4 mL) and the wash layer was decanted to afford the desired product as a 1:1 mixture with imidazole. This was used without further purification. The urea (47 mg, 84 μmol) was dissolved in dichloromethane (2.0 mL), and the solution was treated with TFA (180 μL, 3.3 mmol) and stirred at room temperature overnight. The reaction mixture was diluted with dichloromethane, poured into saturated aqueous NaHCO 3 , and extracted with dichloromethane. The combined organic layers were dried (MgSO 4 ), filtered, and concentrated to an oil. The residue was washed with hexanes, and the wash layer was decanted to afford the desired product as a yellow foam (40 mg, 63% over two steps) in about 20:1 dr (by 1 H NMR): R f =
